Bruton's tyrosine kinase in complex with compound 23

Bruton's tyrosine kinase in complex with compound 23 Descriptor: DIMETHYL SULFOXIDE, Isoform BTK-C of Tyrosine-protein kinase BTK, ~{N}-[(5~{R})-2-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-6,7,8,9-tetrahydro-5~{H}-benzo[7]annulen-5-yl]-3-propan-2-yloxy-azetidine-1-carboxamide Authors: Metrick, C.M, Marcotte, D.J. Deposit date: 2021-02-20 Release date: 2022-01-12 Last modified: 2023-10-18 Method: X-RAY DIFFRACTION (1.69 Å) Cite: Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis. J.Med.Chem., 65, 2022

布鲁顿酪氨酸激酶（Bruton's tyrosine kinase）与化合物23的复合物。描述项：二甲基亚砜（DIMETHYL SULFOXIDE）、酪氨酸蛋白激酶BTK（Tyrosine-protein kinase BTK）的BTK-C亚型、(5R)-2-[2-[(1-甲基吡唑-4-基)氨基]嘧啶-4-基]-6,7,8,9-四氢-5H-苯并环庚烯-5-基]-3-异丙氧基氮杂环丁烷-1-甲酰胺。作者：Metrick, C.M.、Marcotte, D.J.。入库日期：2021-02-20。发布日期：2022-01-12。最后修改日期：2023-10-18。实验方法：X射线衍射（X-RAY DIFFRACTION，分辨率1.69埃）。引用文献：《BIIB091：一种用于治疗多发性硬化的可逆性选择性BTK抑制剂的发现及临床前表征》，发表于J.Med.Chem. 2022年第65卷。